Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 217)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 17.05.24 07:21:04 von
neuester Beitrag 17.05.24 07:21:04 von
Beiträge: 2.942
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 1
Gesamt: 345.967
Gesamt: 345.967
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,4600
USD
-0,68 %
-0,0100 USD
Letzter Kurs 02:00:00 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,25 | +63,04 | |
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 6,2500 | +24,75 | |
| 0,8200 | +15,49 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
FeedbackLive & in Farber...
Lets all hope "Dan" is right at the end of the day...
GALE's Mkt Cap is likely to top $1 B by year's end
Galena's Market Cap (now) is approx $225 mil. With Phase 3 NeuVax Clinical Trials recently fully enrolled; and with increasing Abstral sales; and with Zuplenz sales starting; and with positive progress being reported from all other aspects of the Company's R&D; and with sustaining funds in excess of $50 million, a $1+ Billion GALE valuation is inevitable (IMO). We are, therefore, looking at a relatively unchallenged GALE pps of $4-$5. Keep in mind that the IDMC (Indep. Data Monitoring Committee) will be issuing its statement regarding NeuVax (likely to happen between this mid-summer and year's end). The IDMC statement will read something along the lines of: Having assessed the NeuVax Phase III (PRESENT) clinical data, and as triggered by the study's 70th recurrence, we conclude that Galena should continue the PRESENT Study as planned and without modification. And when this news is released, it's further reasonable and logical that GALE's market cap will be catapulted to exceed $3 + Billion (in excess of $10 pps). Respectfully, Dan
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
GALE's Mkt Cap is likely to top $1 B by year's end
Galena's Market Cap (now) is approx $225 mil. With Phase 3 NeuVax Clinical Trials recently fully enrolled; and with increasing Abstral sales; and with Zuplenz sales starting; and with positive progress being reported from all other aspects of the Company's R&D; and with sustaining funds in excess of $50 million, a $1+ Billion GALE valuation is inevitable (IMO). We are, therefore, looking at a relatively unchallenged GALE pps of $4-$5. Keep in mind that the IDMC (Indep. Data Monitoring Committee) will be issuing its statement regarding NeuVax (likely to happen between this mid-summer and year's end). The IDMC statement will read something along the lines of: Having assessed the NeuVax Phase III (PRESENT) clinical data, and as triggered by the study's 70th recurrence, we conclude that Galena should continue the PRESENT Study as planned and without modification. And when this news is released, it's further reasonable and logical that GALE's market cap will be catapulted to exceed $3 + Billion (in excess of $10 pps). Respectfully, Dan
http://finance.yahoo.com/mbview/threadview/?&bn=12a6b315-348…
Antwort auf Beitrag Nr.: 49.152.506 von Schaeffi am 23.02.15 20:17:55Ganz genau Schaeffi,-(habe wohl zu lang gewartet mit dem reinkopieren)- genau dein beitrag wurde gemeint...Kolbert & Maxim kriegen immer mehr "airtime" im sachen Brustkrebs
thx fürs reinstellen!
thx fürs reinstellen!
..5. März ich bin gespannt...ob der Hammer kommt.
Antwort auf Beitrag Nr.: 49.151.744 von Growth2012 am 23.02.15 19:21:28
http://video.cnbc.com/gallery/?video=3000356693&play=1
bei hat der link nicht funzioniert bzw war was ganz anderes
vielleicht geht derhttp://video.cnbc.com/gallery/?video=3000356693&play=1
Trading Spotlight
Antwort auf Beitrag Nr.: 49.152.071 von lunatics am 23.02.15 19:45:00..ist ja gut, lass mal stecken
Nein - muss ich denn schon?
Antwort auf Beitrag Nr.: 49.151.861 von lunatics am 23.02.15 19:30:37Ich denk Du bist -(noch)- nicht wieder dabei...
Bravo!
GALE wird zum Selbstläufer..
GALE wird zum Selbstläufer..
Antwort auf Beitrag Nr.: 49.151.744 von Growth2012 am 23.02.15 19:21:28und dieses (vollständigkeitshalber ) hinterher...
$7.00 PRICE TARGET BY MAXIM
Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price target of $7, as the company announced that first patient in the NeuVax/Herceptin combination phase II trial has been dosed. The study is aimed at prevention of breast cancer recurrence in high risk HER2 3+ and or HER2 gene-amplified patients.
Kolbert noted, “First patient dosing in any trial is a milestone. It means the trial is really underway and as such, we are excited. • The “PRESENT” phase III trial for NeuVax continues to enroll (and actually over-enroll) patients, with completion on track for January 2015. Endpoints in the trial are based on tumor recurrence, with an interim data analysis expected in 2H15. Preventing the recurrence of breast cancer represents an unmet medical need and a blockbuster opportunity.
) hinterher...$7.00 PRICE TARGET BY MAXIM
Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a price target of $7, as the company announced that first patient in the NeuVax/Herceptin combination phase II trial has been dosed. The study is aimed at prevention of breast cancer recurrence in high risk HER2 3+ and or HER2 gene-amplified patients.
Kolbert noted, “First patient dosing in any trial is a milestone. It means the trial is really underway and as such, we are excited. • The “PRESENT” phase III trial for NeuVax continues to enroll (and actually over-enroll) patients, with completion on track for January 2015. Endpoints in the trial are based on tumor recurrence, with an interim data analysis expected in 2H15. Preventing the recurrence of breast cancer represents an unmet medical need and a blockbuster opportunity.
Durchsuchen
